A pharmacogenomic study identifies an ANK3 gene variant as a predictive biomarker for treatment response to liafensine, a triple reuptake inhibitor, in patients with treatment-resistant depression.
This study validates a neurotransmitter-centric computational pipeline for analyzing EEG spectral power changes in patients taking psychotropic medications, offering a more mechanistic framework for understanding drug effects than traditional class-based approaches.
A recall of 300,000 bottles of the antidepressant Cymbalta (duloxetine) has been issued, necessitating immediate verification of stock and patient counseling regarding potential quality or safety issues.
This case report describes new-onset visual snow syndrome temporally associated with bupropion initiation and resolution upon discontinuation, highlighting a rare but significant neuropsychiatric adverse effect of this antidepressant.
A long-term follow-up study demonstrates that psilocybin combined with psychotherapy provides sustained antidepressant effects for up to 12 months in patients with treatment-resistant depression.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Feb 18 – Jun 19)
- Verify current stock levels and counsel patients on the recent Cymbalta (duloxetine) recall affecting 300,000 bottles to ensure medication quality and safety.
- Consider ANK3 gene variant testing as a potential predictive biomarker for treatment response to liafensine in cases of treatment-resistant depression.
- Utilize centanafadine as a novel pharmacological option for ADHD in both adult and pediatric populations when standard therapies are insufficient or not tolerated.
- Discuss the potential for sustained antidepressant effects up to 12 months with psilocybin-assisted psychotherapy as an emerging intervention for treatment-resistant depression.
- Systematically assess history of childhood maltreatment in schizophrenia patients, as it is a critical predictor of treatment resistance and should guide antipsychotic selection.
- Prefer antipsychotic-benzodiazepine combinations over haloperidol monotherapy for rapid tranquilization in emergency settings to reduce extrapyramidal side effects, while monitoring for hypotension.
- Be aware that bupropion initiation can rarely trigger new-onset visual snow syndrome, which typically resolves upon discontinuation of the medication.
- Re-evaluate prescribing patterns for lithium in youth with bipolar disorder, as it remains underutilized despite being a first-line treatment while SGA and antidepressant use is high.
- Apply neurotransmitter-centric computational pipelines to EEG spectral power analysis when investigating mechanistic drug effects, offering greater precision than traditional class-based approaches.
Diagnosis & Treatment 3
A study indicates that psilocybin combined with psychotherapy produces sustained antidepressant effects over a 12-month period, highlighting the potential long-term efficacy of this novel psychotropic treatment for depression.
A network meta-analysis indicates that antipsychotic-benzodiazepine combinations are superior to haloperidol monotherapy for rapid tranquilization in emergency settings, though they carry a higher risk of hypotension while haloperidol is associated with extrapyramidal side effects.
This commentary highlights childhood maltreatment as a critical predictor of treatment resistance in schizophrenia, suggesting its assessment is vital for optimizing antipsychotic pharmacotherapy trials and clinical management.
Journal Article 1
A retrospective cohort study reveals that lithium dispensing remains low in Dutch youth with bipolar disorder despite its first-line status, with a concurrent high rate of prior or concomitant use of SGAs and antidepressants.
Drug Development 2
A Phase 2 experimental medicine study shows that the novel 5-HT4 receptor agonist PF-04995274 increases hippocampal activity during memory encoding in unmedicated depressed patients, supporting its development as a cognitive-enhancing adjunct for Major Depressive Disorder.
Centanafadine demonstrates efficacy in clinical studies for treating ADHD in both adult and pediatric populations, representing a new pharmacological option for this condition.